If the $18B drug distributor opioid settlement, as reported last night by the Wall Street Journal, covers nearly all outstanding cases, and does not include any accelerated upfront payments for the industry, then it would likely be viewed net positive by investors and could lead to multiple expansion from current share levels, Barclays analyst Steve Valiquette tells investors in a research note. The analyst believes the possibility of a settlement is greater over the next week ahead of the start of the Ohio multi-district litigation. To reflect a higher probability of a favorable settlement, Valiquette raised his price target for McKesson (MCK) to $156 from $144 while keeping an Equal Weight rating on the shares.